Cowen And Company, LLC Biomarin Pharmaceutical Inc Transaction History

Cowen And Company, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$76.22 - $98.51 $1.74 Million - $2.25 Million	22,865 New	22,865 $2.2 Million
Q2 2022 Aug 05, 2022	SELL	$71.48 - $86.85 $665,621 - $808,747	-9,312 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $237,398 - $296,237	3,196 Added 52.26%	9,312 $718,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $438,639 - $559,430	6,116 New	6,116 $540,000
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $384,691 - $439,743	-5,145 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $380,268 - $427,002	-5,036 Reduced 49.46%	5,145 $429,000
Q1 2021 May 04, 2021	BUY	$74.73 - $90.69 $754,623 - $915,787	10,098 Added 12166.27%	10,181 $769,000
Q3 2020 Nov 03, 2020	BUY	$71.87 - $131.03 $5,965 - $10,875	83 New	83 $6,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.